Figure 31. Forest plot of effects of therapy by drug class on pulmonary vascular resistance. This figure shows a forest plot from 11 RCTs representing 877 patients reported the effects of monotherapy or combination therapy for PAH on PVR as assessed by right heart catheterization at 8 to 16 weeks after initiating treatment. The summary estimate for endothelin antagonists was −217.5 mm Hg/liter/min (95% CI, −424.4 to −10.7). The single study that evaluated a phosphodiesterase inhibitor (sildenafil) reported an improvement in PVR associated with active treatment of −224.7 mm Hg/liter/min (CI, −339.6 to −109.8). Meta-analysis of the five studies that evaluated a prostanoid as the active treatment demonstrated an improvement in PVR associated with active treatment of −256.2 mm Hg/liter/min (CI, −440.4 to −71.9).

Figure 31Forest plot of effects of therapy by drug class on pulmonary vascular resistance

CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

From: Results

Cover of Pulmonary Arterial Hypertension: Screening, Management, and Treatment
Pulmonary Arterial Hypertension: Screening, Management, and Treatment [Internet].
Comparative Effectiveness Reviews, No. 117.
McCrory DC, Coeytaux RR, Schmit KM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.